In 2025, hospitals and health systems have said they are focused on two things: financial stability and patient experience. In a LinkedIn poll, Becker’s asked: Which of these will rank highest among ...
Phase 3 persevERA missed the primary endpoint, with no statistically significant improvement in investigator-assessed PFS for giredestrant plus palbociclib versus letrozole plus palbociclib in the ITT ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial. The British-Swedish pharmaceutical company said Wednesday that the phase III of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results